The head of China's drug-safety agency is under investigation for alleged corruption. David Cyranoski looks at how the inquiry might affect the country's fast-growing pharmaceutical industry.
This is a preview of subscription content, log in via an institution to check access.
Related links
Related links
Related links in Nature Research
Can China bring its own pipeline to the market?
Chinese biotech hamstrung by production issues
Poor enforcement could jeopardize China's drug innovation policy
Related external links
Rights and permissions
About this article
Cite this article
China's deadly drug problem. Nature 446, 598–599 (2007). https://doi.org/10.1038/446598a
Published:
Issue Date:
DOI: https://doi.org/10.1038/446598a
- Springer Nature Limited
This article is cited by
-
Stem-cell laws in China fall short
Nature (2010)
-
China tightens up
Nature (2007)